Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1997016202) CYTOKINES AND THEIR USE IN TREATMENT AND/OR PROPHYLAXIS OF BREAST CANCER
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1997/016202 International Application No.: PCT/AU1996/000676
Publication Date: 09.05.1997 International Filing Date: 25.10.1996
Chapter 2 Demand Filed: 30.04.1997
IPC:
A61K 38/18 (2006.01) ,A61K 38/19 (2006.01) ,A61K 38/20 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
18
Growth factors; Growth regulators
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
19
Cytokines; Lymphokines; Interferons
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
19
Cytokines; Lymphokines; Interferons
20
Interleukins
Applicants:
AMRAD OPERATIONS PTY. LTD. [AU/AU]; 17-27 Cotham Road Kew, VIC 3101, AU (AllExceptUS)
DOUGLAS, Andrea, Margaret [AU/AU]; AU (UsOnly)
BEGLEY, Colin, Glenn [AU/AU]; AU (UsOnly)
Inventors:
DOUGLAS, Andrea, Margaret; AU
BEGLEY, Colin, Glenn; AU
Agent:
HUGHES, E., John, L. ; Davies Collison Cave 1 Little Collins Street Melbourne, VIC 3000, AU
Priority Data:
PN 624227.10.1995AU
PN 624327.10.1995AU
PN 896627.03.1996AU
PO 036407.06.1996AU
Title (EN) CYTOKINES AND THEIR USE IN TREATMENT AND/OR PROPHYLAXIS OF BREAST CANCER
(FR) CYTOKINES ET LEUR UTILISATION DANS LE TRAITEMENT ET/OU LA PROPHYLAXIE DU CANCER DU SEIN
Abstract:
(EN) The present invention relates generally to a method for the treatment or prophylaxis of animals including humans suffering from or predisposed to breast cancer or other related cancers which comprises the use of cytokines and/or functionally active derivatives, hybrids and/or analogs thereof and to pharmaceutical compositions comprising same as therapeutic agents. In particular, but not exclusively, the present invention is directed to the use of cytokines which are ligands of members of the haemopoietin receptor super family or their derivatives, hybrids or analogs as therapeutic agents. The present application also contemplates breast cancer therapies and methods of suppressing growth of normal breast cells or breast cancer cells by the use of one or more cytokines optionally in combination with other therapeutic agents as well as the use of agonists or antagonists of cytokine activity. Particularly preferred are oncostatin M (OSM) and leukaemia inhibitory factor (LIF).
(FR) Méthode de traitement ou de prophylaxie d'animaux, y compris d'être humains, souffrant de cancer du sein ou d'autres cancers associés ou prédisposés à souffrir desdits cancers, qui consiste à utiliser des cytokines et/ou des dérivés, des hybrides et/ou des analogues actifs fonctionnels desdites cytokines, ainsi que des compositions pharmaceutiques comportant lesdites cytokines en tant qu'agents thérapeutiques. En particulier, mais non exclusivement, la présente invention concerne l'utilisation de cytokines qui sont des ligands de membres de la superfamille des récepteurs de l'hématopoïétine ou leurs dérivés, hybrides ou analogues en tant qu'agents thérapeutiques. La présente invention concerne également des thérapies pour le cancer du sein et des procédés destinés à empêcher la croissance de cellules mammaires normales ou de cellules cancéreuses mammaires par l'utilisation d'une ou plusieurs cytokines, éventuellement en combinaison avec d'autres agents thérapeutiques, ainsi que par l'utilisation d'agonistes ou d'antagonites de l'activité des cytokines. Les substances particulièrement préférées sont l'oncostatine M (OSM) et le facteur inhibiteur de la leucémie LIF.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN
African Regional Intellectual Property Organization (ARIPO) (KE, LS, MW, SD, SZ, UG)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP0871472US20020106347AU1996072676